![](https://www.stoketherapeutics.com/wp-content/uploads/2021/09/masthead_disease-areas@2x.jpg)
Stoke’s proprietary proprietary research platform, TANGO, has broad therapeutic potential. Our ongoing research programs currently focus on two severe diseases.
Our lead clinical program is focused on Dravet syndrome, a severe and progressive genetic epilepsy characterized by frequent, prolonged and refractory seizures that usually begin within the first year of life. We are also examining a preclinical target for Autosomal Dominant Optic Atrophy (ADOA) a severe, progressive optic nerve disorder.
![](https://www.stoketherapeutics.com/wp-content/uploads/photo_disease-areas_dravet_v2.jpg)
Dravet Syndrome
Dravet syndrome affects an estimated 35,000 people in the United States, Canada, Japan, Germany, France and the UK.
![](https://www.stoketherapeutics.com/wp-content/uploads/photo_disease-areas_adoa_v2.jpg)
Autosomal Dominant Optic Atrophy (ADOA)
ADOA is the most common inherited optic nerve disorder seen in clinical practice.
![](https://www.stoketherapeutics.com/wp-content/uploads/photo_disease-areas_rett-syndrome-600x400.jpg)
Rett Syndrome
Rett syndrome is a rare, debilitating neurological disorder that occurs primarily in females following apparently normal development for the first six months of life.
![](https://www.stoketherapeutics.com/wp-content/uploads/photo_disease-areas_syngap1.jpg)
SYNGAP1
SYNGAP1 is a rare neurological disorder characterized by moderate to severe intellectual disability that is evident in early childhood.
![](https://www.stoketherapeutics.com/wp-content/uploads/photo_disease-areas_pipeline.jpg)
Our Pipeline
Using the Company’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels.